Compare
AbbVie vs Krystal Biotech (ABBV vs KRYS)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Krystal Biotech (KRYS) +50.5%; so far this year the figures are +27.5% and +22.0%.
AbbVie is the larger company by market value, about 57.7 times the size of Krystal Biotech.
On trailing earnings, ABBV trades at 50.1 times and KRYS at 40.8 times.
Revenue grew +10.7% at ABBV and +26.0% at KRYS over the last year.
ABBV yields 2.38%. KRYS pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | KRYS | |
|---|---|---|
| Price | $291.31 | $300.88 |
| 1-day | +1.07% | +0.21% |
| YTD | +27.49% | +22.04% |
| 1 year | +34.39% | +50.53% |
| 3 years | +104.47% | +152.18% |
| Market cap | $514.9B | $8.9B |
| P/E | 50.1 | 40.8 |
| P/S | 7.80 | 18.97 |
| P/B | — | 6.21 |
| Revenue growth | +10.70% | +26.00% |
| EPS growth | +340.20% | +10.30% |
| Gross margin % | 73.7 | — |
| Net margin % | 15.7 | 47.9 |
| ROE % | — | 15.7 |
| Debt / equity | — | 0.00 |
| FCF yield % | 3.7 | 3.5 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 0.75 |
| RSI (14) | 59.7 | 39.9 |
| Technical rating |